Target Name: TRPM6
NCBI ID: G140803
Review Report on TRPM6 Target / Biomarker Content of Review Report on TRPM6 Target / Biomarker
TRPM6
Other Name(s): HOMG | Transient receptor potential cation channel subfamily M member 6, transcript variant a | TRPM6 variant b | transient receptor potential cation channel subfamily M member 6 | melastatin-related TRP cation channel 6 | HMGX | HSH | Transient receptor potential cation channel subfamily M member 6 (isoform a) | Melastatin-related TRP cation channel 6 | Transient receptor potential cation channel subfamily M member 6, transcript variant c | Channel kinase 2 | HOMG1 | Transient receptor potential cation channel subfamily M member 6 (isoform b) | LTRPC6 channel kinase 2 | TRPM6 variant a | Transient receptor potential cation channel subfamily M member 6 | Transient receptor potential cation channel subfamily M member 6 (isoform c) | channel kinase 2 | Transient receptor potential cation channel subfamily M member 6, transcript variant b | TRPM6_HUMAN | CHAK2 | TRPM6 variant c

TRPM6: A Protein Involved in Pain Signaling and Other Physiological Processes

TRPM6 (Transient receptor potential cation channel subfamily 6) is a protein that is expressed in many different tissues throughout the body. It is involved in the sense of touch and pressure, and is thought to play a role in the development of pain.

Recent studies have suggested that TRPM6 may be a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and pain. This is because TRPM6 is known to be involved in the regulation of pain signaling, and alterations in its expression or function have been observed in a variety of diseases.

One potential mechanism by which TRPM6 may be involved in pain signaling is by modulating the activity of other pain-related genes. For example, studies have shown that TRPM6 can interact with the protein TrPV1, which is involved in the sensation of pain. By modulating TrPV1 activity, TRPM6 has been shown to influence the formation of pain-related neural circuits in the brain.

Another potential mechanism by which TRPM6 may be involved in pain signaling is by modulating the activity of sensory neurons. TRPM6 is known to interact with a protein called NIPA (Nucleotide-Inositol Pyruvate), which is involved in the production of intracellular signaling cides. By modulating NIPA activity, TRPM6 has been shown to influence the release of pain-related sensory information from neurons.

In addition to its potential role in pain signaling, TRPM6 is also thought to be involved in the regulation of other physiological processes. For example, studies have shown that TRPM6 is involved in the regulation of inflammation, and that alterations in its expression or function can affect the outcomes of various inflammatory diseases.

Given the potential involvement of TRPM6 in pain signaling and other physiological processes, it is a promising target for drug development. Currently, several compounds have been shown to interact with TRPM6 and to influence its function, including small molecules, peptides, and antibodies. Further research is needed to fully understand the mechanisms of TRPM6's role in pain signaling and other physiological processes, and to develop safe and effective drugs or biomarkers based on this knowledge.

Protein Name: Transient Receptor Potential Cation Channel Subfamily M Member 6

Functions: Essential ion channel and serine/threonine-protein kinase. Crucial for magnesium homeostasis. Has an important role in epithelial magnesium transport and in the active magnesium absorption in the gut and kidney. Isoforms of the type M6-kinase lack the ion channel region

The "TRPM6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRPM6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TRPM7 | TRPM8 | TRPS1 | TRPT1 | TRPV1 | TRPV2 | TRPV3 | TRPV4 | TRPV5 | TRPV6 | TRR-ACG1-2 | TRRAP | TRU-TCA2-1 | TRUB1 | TRUB2 | Trypanosome lytic factor 1 | Trypanosome lytic factor 2 | Trypsin | Tryptase | Tryptophan 5-Monooxygenase | TSACC | TSBP1 | TSBP1-AS1 | TSC1 | TSC2 | TSC22D1 | TSC22D1-AS1 | TSC22D2 | TSC22D3 | TSC22D4 | TSEN15 | TSEN2 | TSEN2P1 | TSEN34 | TSEN54 | TSFM | TSG1 | TSG101 | TSGA10 | TSGA10IP | TSGA13 | TSHB | TSHR | TSHZ1 | TSHZ2 | TSHZ3 | TSHZ3-AS1 | TSIX | TSKS | TSKU | TSLP | TSN | TSNARE1 | TSNAX | TSNAX-DISC1 | TSNAXIP1 | TSPAN1 | TSPAN10 | TSPAN11 | TSPAN12 | TSPAN13 | TSPAN14 | TSPAN15 | TSPAN16 | TSPAN17 | TSPAN18 | TSPAN19 | TSPAN2 | TSPAN3 | TSPAN31 | TSPAN32 | TSPAN33 | TSPAN4 | TSPAN5 | TSPAN6 | TSPAN7 | TSPAN8 | TSPAN9 | TSPEAR | TSPEAR-AS1 | TSPEAR-AS2 | TSPO | TSPO2 | TSPOAP1 | TSPOAP1-AS1 | TSPY1 | TSPY2 | TSPY26P | TSPY3 | TSPY4 | TSPYL1 | TSPYL2 | TSPYL4 | TSPYL5 | TSPYL6 | TSR1 | TSR2 | TSR3 | TSSC2 | TSSC4